🇺🇸 FDA
Patent

US 10758613

Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 10758613 (Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells) held by THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH
Grant date
Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K2039/545, A61K31/337